Valneva Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019
Major R&D milestones achieved in 2018, double-digit product sales revenue growth delivered; Lyme and chikungunya programs expected to advance further in 2019
David Lawrence, Valneva’s Chief Financial Officer, commented, “2018 has been a significantyear for Valneva. Webrokethe €100 millionthresholdfor product sales, made significant progress inR&Dand successfully executeda strategic capital raiseas part of our capital formation strategy.2019isalready off to an excellent start with the new DoDIXIARO®supply contractand positive Phase 1 interim results for our chikungunya vaccine candidate.We are excited aboutcontinuing to execute our strategyand unlocking shareholder value.”